Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

Be on the lookout for the phase 3 trial of pembro/docetaxel. Here are the phase 2 results of the single arm study.

Read the full article here

Related Articles